KR102004558B1 - 선택적 전달 분자 및 사용 방법 - Google Patents

선택적 전달 분자 및 사용 방법 Download PDF

Info

Publication number
KR102004558B1
KR102004558B1 KR1020147002685A KR20147002685A KR102004558B1 KR 102004558 B1 KR102004558 B1 KR 102004558B1 KR 1020147002685 A KR1020147002685 A KR 1020147002685A KR 20147002685 A KR20147002685 A KR 20147002685A KR 102004558 B1 KR102004558 B1 KR 102004558B1
Authority
KR
South Korea
Prior art keywords
delete delete
amino acid
seq
amino acids
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147002685A
Other languages
English (en)
Korean (ko)
Other versions
KR20140063587A (ko
Inventor
준지에 리우
제서스 곤잘레즈
Original Assignee
아벨라스 바이오사이언시즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벨라스 바이오사이언시즈 인코포레이티드 filed Critical 아벨라스 바이오사이언시즈 인코포레이티드
Publication of KR20140063587A publication Critical patent/KR20140063587A/ko
Application granted granted Critical
Publication of KR102004558B1 publication Critical patent/KR102004558B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6432—Quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
KR1020147002685A 2011-07-29 2012-07-27 선택적 전달 분자 및 사용 방법 Expired - Fee Related KR102004558B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513287P 2011-07-29 2011-07-29
US61/513,287 2011-07-29
PCT/US2012/048732 WO2013019681A2 (en) 2011-07-29 2012-07-27 Selective delivery molecules and methods of use

Publications (2)

Publication Number Publication Date
KR20140063587A KR20140063587A (ko) 2014-05-27
KR102004558B1 true KR102004558B1 (ko) 2019-07-26

Family

ID=47629864

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147002685A Expired - Fee Related KR102004558B1 (ko) 2011-07-29 2012-07-27 선택적 전달 분자 및 사용 방법

Country Status (12)

Country Link
US (6) US9278144B2 (enExample)
EP (2) EP3473273A1 (enExample)
JP (1) JP6124150B2 (enExample)
KR (1) KR102004558B1 (enExample)
CN (1) CN103874512B (enExample)
AU (1) AU2012290318B2 (enExample)
CA (1) CA2841249C (enExample)
DK (1) DK2736533T3 (enExample)
EA (1) EA030795B1 (enExample)
ES (1) ES2683377T3 (enExample)
MX (1) MX350082B (enExample)
WO (1) WO2013019681A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
WO2010101628A2 (en) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
CN102858794A (zh) 2009-07-15 2013-01-02 加州大学董事会 细胞内吸收可控制的肽
US9278144B2 (en) * 2011-07-29 2016-03-08 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
WO2014120837A2 (en) * 2013-01-29 2014-08-07 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
WO2014120974A1 (en) * 2013-01-30 2014-08-07 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
WO2014176284A1 (en) * 2013-04-22 2014-10-30 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
PL405046A1 (pl) * 2013-08-12 2015-02-16 Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Pan Genetycznie kodowany oparty na FRET biosensor aktywności MMP-9 i jego zastosowanie
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
US11458208B2 (en) 2016-06-06 2022-10-04 Asclepiumm Taiwan Co., Ltd Desmoglein 2 antibody fusion proteins for drug delivery
EP3876196A1 (en) 2017-04-07 2021-09-08 Avelas Biosciences, Inc. Ratiometric fluorescence imaging methods
US10450119B2 (en) * 2017-06-22 2019-10-22 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating
EP3641951B1 (en) 2017-06-22 2023-09-20 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited organic coating
CN108096255B (zh) * 2017-12-28 2019-11-12 北京大学 地夫可特用于抑制或治疗胰腺癌的用途
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
US20220347306A1 (en) * 2018-04-16 2022-11-03 Avelas Biosciences, Inc. Selective delivery of therapeutic and imaging agents
US12173349B2 (en) 2018-09-25 2024-12-24 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
WO2020150560A1 (en) 2019-01-17 2020-07-23 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
CN110075322B (zh) * 2019-05-20 2021-07-06 复旦大学附属妇产科医院 一种靶向GnRH受体的近红外荧光成像探针及其制备方法与应用
WO2021061752A1 (en) * 2019-09-23 2021-04-01 Neonc Technologies, Inc. Pharmaceutical compositions comprising poh derivatives
WO2024233344A1 (en) * 2023-05-05 2024-11-14 The United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating tendon and bone injuries

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060041105A1 (en) 2003-10-31 2006-02-23 The Regents Of The University Of California Peptides whose uptake by cells is controllable
WO2011008996A2 (en) 2009-07-15 2011-01-20 The Regents Of The University Of California Peptides whose uptake in cells is controllable

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466919A (en) 1982-12-16 1984-08-21 Monsanto Company Peptide substrates for mammalian collagenase
US4507389A (en) 1982-12-16 1985-03-26 Monsanto Company Determination of collagenase by reacting with peptide substrates
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
AU8137694A (en) * 1993-11-16 1995-06-06 Resolution Pharmaceuticals Inc. Immobilized labelling method
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
JP2002518521A (ja) 1998-06-20 2002-06-25 ワシントン・ユニバーシティ 医用画像解析、診断および治療のための膜透過性ペプチド錯体
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020009786A1 (en) 2000-04-18 2002-01-24 Tang Y. Tom Novel nucleic acids and polypeptides
WO2003006043A1 (en) 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
US7371364B2 (en) 2003-08-15 2008-05-13 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
US7431915B2 (en) * 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
CN104998273A (zh) 2003-11-06 2015-10-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
NZ548255A (en) 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
AU2009212311B8 (en) 2004-07-21 2013-05-30 Ambrx, Inc. Modified leptin polypeptides and their uses
CA2611297A1 (en) * 2005-06-07 2007-01-18 Universite Des Sciences Et Technologies De Lille Use of ionic matrices for maldi mass spectrometry analysis of tissue sections
TW201004647A (en) 2008-05-20 2010-02-01 Sigma Tau Ind Farmaceuti Novel dual targeting antitumoural conjugates
WO2010014236A2 (en) * 2008-07-30 2010-02-04 The University Of North Carolina At Chapel Hill Acylhydrazone-based cleavable linkers
US9579400B2 (en) 2008-09-23 2017-02-28 The Regents Of The University Of California Nanocarriers for drug delivery
CA2737026C (en) 2008-09-26 2019-12-24 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
KR101095841B1 (ko) 2009-02-19 2011-12-21 주식회사 나이벡 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도
JP2012520856A (ja) 2009-03-19 2012-09-10 ゼネラル・エレクトリック・カンパニイ 光学イメージング剤
WO2010121023A2 (en) 2009-04-15 2010-10-21 The Regents Of The University Of California Peptides and aptamers for targeting of neuron or nerves
EP2523600A4 (en) * 2010-01-12 2015-07-15 Univ Ben Gurion TARGETED RELEASE SYSTEMS FOR DIAGNOSTIC APPLICATIONS
JP5580625B2 (ja) 2010-03-03 2014-08-27 住友化学株式会社 メタンスルホン酸アルキルエステル溶液の製造方法
US20120055055A1 (en) 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
TR201901259T4 (tr) 2011-02-10 2019-02-21 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Karaciğere özgü tanı için hidrofobik modifiye peptidler.
US9278144B2 (en) * 2011-07-29 2016-03-08 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
WO2014120837A2 (en) 2013-01-29 2014-08-07 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
WO2014120974A1 (en) 2013-01-30 2014-08-07 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
WO2014176284A1 (en) 2013-04-22 2014-10-30 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060041105A1 (en) 2003-10-31 2006-02-23 The Regents Of The University Of California Peptides whose uptake by cells is controllable
WO2011008996A2 (en) 2009-07-15 2011-01-20 The Regents Of The University Of California Peptides whose uptake in cells is controllable

Also Published As

Publication number Publication date
EA201490385A1 (ru) 2014-07-30
JP6124150B2 (ja) 2017-05-10
US20170044214A1 (en) 2017-02-16
MX2014001138A (es) 2014-07-22
US20160220707A1 (en) 2016-08-04
AU2012290318B2 (en) 2016-09-01
US20190119327A1 (en) 2019-04-25
ES2683377T3 (es) 2018-09-26
WO2013019681A3 (en) 2013-07-11
US20150031852A1 (en) 2015-01-29
KR20140063587A (ko) 2014-05-27
CA2841249C (en) 2023-09-26
JP2014521661A (ja) 2014-08-28
US20180057536A1 (en) 2018-03-01
US10570178B2 (en) 2020-02-25
EP2736533B1 (en) 2018-07-04
MX350082B (es) 2017-08-24
CA2841249A1 (en) 2013-02-07
EA030795B1 (ru) 2018-09-28
EP2736533A2 (en) 2014-06-04
US10239919B2 (en) 2019-03-26
US9371367B1 (en) 2016-06-21
AU2012290318A1 (en) 2014-01-23
EP3473273A1 (en) 2019-04-24
US9840537B2 (en) 2017-12-12
US20160152670A1 (en) 2016-06-02
US9504763B2 (en) 2016-11-29
CN103874512B (zh) 2016-11-16
DK2736533T3 (en) 2018-08-06
US9278144B2 (en) 2016-03-08
EP2736533A4 (en) 2015-03-04
WO2013019681A2 (en) 2013-02-07
HK1197184A1 (en) 2015-01-09
CN103874512A (zh) 2014-06-18

Similar Documents

Publication Publication Date Title
KR102004558B1 (ko) 선택적 전달 분자 및 사용 방법
US20200376013A1 (en) Selective drug delivery compositions and methods of use
US10363313B2 (en) PSMA ligands and uses thereof
JP2023511073A (ja) 好中球エラスターゼ結合ペプチドおよびその組成物
WO2019183633A1 (en) Psma targeted conjugate compounds and uses thereof
US20220001011A1 (en) Photodynamic therapy composition
US20220347306A1 (en) Selective delivery of therapeutic and imaging agents
US20210079039A1 (en) Compositions and methods for the selective delivery of therapeutic and imaging agents
HK1197184B (en) Selective delivery molecules and methods of use
CN118574643A (zh) 结合磷脂酰丝氨酸和Toll样受体的缀合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230723

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230723